|
1.
|
|
10 p, 496.7 KB |
Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in elderly patients with relapsed multiple myeloma : IKEMA subgroup analysis
/
Facon, Thierry (Lille University Hospital) ;
Moreau, Philippe (University of Nantes) ;
Martin, Thomas G. (University of California San Francisco) ;
Spicka, Ivan (Charles University and General Hospital, Prague, Czech Republic) ;
Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Koh, Youngil (Seoul National University Hospital, South Korea) ;
Lim, Andrew (Austin & Repatriation Medical Center, Heidelberg, Victoria, Australia) ;
Mikala, Gabor (South Pest Central Hospital, Budapest, Hungary) ;
Rosiñol, Laura (Hospital Clínic i Provincial de Barcelona) ;
Yağci, Münci (Gazi University, Ankara, Turkey) ;
Cavo, Michele (Bologna University School of Medicine, Italy) ;
Yong, Kwee (University College Hospital, London, UK) ;
Risse, Marie Laure (Sanofi R&D, Vitry-Sur-Seine, France) ;
Asset, Gaëlle (Sanofi R&D, Chilly-Mazarin, France) ;
Schwab, Sandrine (Sanofi R&D, Chilly-Mazarin, France) ;
Martinez, Gracia (Hospital das Clínicas de São Paulo, Brazil)
In this subgroup analysis of the randomized, Phase 3 IKEMA study (NCT03275285), we evaluated efficacy and safety of the anti-CD38 monoclonal antibody isatuximab (Isa) in combination with carfilzomib-dexamethasone (Isa-Kd) versus Kd in older (≥70 years of age, n = 86) and younger (<70 years, n = 216) patients with relapsed multiple myeloma (MM). [...]
2022 -  10.1002/hon.3038
Hematological Oncology, Vol. 40 Núm. 5 (december 2022) , p. 1020-1029
|
|
|
2.
|
|
9 p, 1.5 MB |
Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma : updated results from IKEMA, a randomized Phase 3 study
/
Martin, Thomas (University of California at San Francisco, USA) ;
Dimopoulos, Meletios (University of Athens, Greece) ;
Mikhael, Joseph (Translational Genomics Research Institute. City of Hope Cancer Center, Phoenix, USA) ;
Yong, Kwee (University College Hospital, London, UK) ;
Capra, Marcelo (Centro Integrado de Hematologia e Oncologia. Hospital Mãe de Deus, Porto Alegre, Brazil) ;
Facon, Thierry (Lille University Hospital, France) ;
Hajek, Roman (University of Ostrava, Czech Republic) ;
Špička, Ivan (Department of Hematology. 1st Faculty of Medicine. Charles University and General Hospital, Prague, Czech Republic) ;
Baker, Ross (Murdoch University, Perth, Australia) ;
Kim, Kihyun (Sungkyunkwan University School of Medicine, Seoul, South Korea) ;
Martinez, Gracia (Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, Brazil) ;
Min, Chang-Ki (The Catholic University of Korea) ;
Pour, Ludek (University Hospital Brno (República Txeca)) ;
Leleu, Xavier (Service d'Hématologie et Thérapie Cellulaire. CHU and CIC Inserm, France) ;
Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Koh, Youngil (Seoul National University Hospital, Seoul, South Korea) ;
Suzuki, Kenshi (Japanese Red Cross Medical Center, Tokyo, Japan) ;
Casca, France (Ividata Life Science, Levallois-Perret, France) ;
Macé, Sandrine (Sanofi, R&D, Chilly-Mazarin, France) ;
Risse, Marie-Laure (Sanofi, R&D, Vitry-sur-Seine, France) ;
Moreau, Philippe (University Hospital Hôtel-Dieu, Nantes, France)
Longer-term outcomes with the anti-CD38 antibody isatuximab in combination with carfilzomib-dexamethasone (Isa-Kd) were evaluated in the randomized Phase 3 trial IKEMA (NCT03275285), in a prespecified, follow-up analysis of progression-free survival (PFS, primary study endpoint), final complete response (CR) using Hydrashift Isa immunofixation assay, minimal residual disease (MRD) negativity, and safety. [...]
2023 - 10.1038/s41408-023-00797-8
Blood Cancer Journal, Vol. 13 Núm. 1 (december 2023)
|
|
|
3.
|
|
9 p, 982.6 KB |
Isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma patients with high-risk cytogenetics : IKEMA subgroup analysis
/
Spicka, Ivan (Charles University and General Hospital) ;
Moreau, Philippe (University of Nantes) ;
Martin, Thomas G. (University of California San Francisco) ;
Facon, Thierry (Lille University Hospital) ;
Martínez, Gracia (Hospital das Clínicas de Faculdade de Medicina da Universidade de São Paulo) ;
Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Koh, Youngil (Seoul National University Hospital) ;
Lim, Andrew (Austin and Repatriation Medical Center) ;
Mikala, Gabor (South Pest Central Hospital) ;
Rosiñol, Laura (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Yağci, Münci (Gazi University) ;
Cavo, Michele (Università di Bologna) ;
Risse, Marie-Laure (Sanofi (França)) ;
Asset, Gaëlle (Sanofi (França)) ;
Macé, Sandrine (Sanofi (França)) ;
Van de Velde, Helgi (Sanofi) ;
Yong, Kwee (University College Hospital) ;
Universitat Autònoma de Barcelona
Introduction: The presence of high-risk chromosomal abnormalities [t(4;14), del(17p), and t(14;16)] has been linked with inferior outcomes in patients with multiple myeloma (MM). A prespecified interim analysis of the Phase 3 IKEMA study (NCT03275285) demonstrated that isatuximab (Isa) + carfilzomib (K) and dexamethasone (d; Isa-Kd) significantly improved progression-free survival (PFS) versus Kd in patients with relapsed MM. [...]
2022 - 10.1111/ejh.13835
European Journal of Haematology, Vol. 109 Núm. 5 (november 2022) , p. 504-512
|
|
|
4.
|
|
8 p, 1.6 MB |
Unplanned admissions for patients with myeloma in the UK : Low frequency but high costs
/
Kolovos, Spyros (University of Oxford. Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences) ;
Nador, Guido (Oxford University Hospitals NHS Trust) ;
Kishore, Bhuvan (Heart of England NHS Foundation Trust) ;
Streetly, Matthew (King's College London) ;
Rabin, Neil K. (Department of Haematology, University College London Hospitals NHS Foundation Trust) ;
Chantry, Andrew D. (Sheffield Teaching Hospitals NHS Foundation Trust (Sheffield, Regne Unit)) ;
Yong, Kwee (UCL Cancer Institute (Londres, Regne Unit)) ;
Ashcroft, John (Department of Haematology, Mid Yorkshire NHS Trust) ;
Bowcock, Stella (King's College Hospital NHS Foundation Trust) ;
Drayson, Mark T. (Institute of Immunology and Immunotherapy, University of Birmingham) ;
Ramasamy, Karthik (Oxford University Hospitals NHS Trust) ;
Prieto-Alhambra, Daniel (Universitat Autònoma de Barcelona) ;
Cooper, Cyrus (NIHR Oxford Biomedical Research Centre) ;
Javaid, M. Kassim (Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford) ;
Pinedo-Villanueva, Rafael (Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford)
Multiple myeloma (MM) is associated with high healthcare resource utilisation and increasing hospitalisation rates. The aim of this study was to characterise the hospital use by patients with MM in the English National Health Service (NHS). [...]
2019 - 10.1016/j.jbo.2019.100243
Journal of Bone Oncology, Vol. 17 (august 2019)
|
|
|
5.
|
|
10 p, 809.5 KB |
The MUK five protocol : a phase II randomised, controlled, parallel group, multi-centre trial of carfilzomib, cyclophosphamide and dexamethasone (CCD) vs. cyclophosphamide, bortezomib (Velcade) and dexamethasone (CVD) for first relapse and primary refractory multiple myeloma
/
Brown, Sarah (Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK) ;
Hinsley, Samantha (Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK) ;
Ballesteros Silva, Mónica Patricia (Universitat Autònoma de Barcelona. Departament de Pediatria, Obstetrícia i Ginecologia i Medicina Preventiva i Salut Pública) ;
Bourne, Sue (Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK) ;
McGarry, Paul (Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK) ;
Sherratt, Debbie (Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK) ;
Flanagan, Louise (Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK) ;
Gregory, Walter (Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK) ;
Cavenagh, Jamie (St Bartholomew's Hospital (Regne Unit)) ;
Owen, Roger (HMDS Laboratory, St James's University Hospital, Leeds, UK) ;
Williams, Cathy (Centre for Clinical Haematology, Nottingham University Hospitals, Nottingham, UK) ;
Kaiser, Martin (The Institute of Cancer Research, Sutton, UK) ;
Low, Eric (Myeloma UK, Edinburgh, UK) ;
Yong, Kwee (UCL Cancer Institute (Londres, Regne Unit))
Multiple myeloma is a plasma cell tumour with an annual incidence in the UK of approximately 40-50 per million i. e. about 4500 new cases per annum. The triple combination cyclophosphamide, bortezomib (Velcade®) and dexamethasone (CVD) is an effective regimen at relapse and has emerged in recent years as the standard therapy at first relapse in the UK. [...]
2016 - 10.1186/s12878-016-0053-9
BMC Hematology, Vol. 16 (may 2016)
|
|
visitant ::
identificació
alerta personal via correu electrònic o subscribiu-vos al 
canal RSS.
